Work

Supplementary Figure 2A from A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report

Year: 2023

Type: supplementary-materials

Abstract: PDF file, 39K, Plasma soluble VEGFR2 (A) and Placental Growth Factor (B) concentrations prior to therapy (baseline) and at the end of cycle 1 (steady state).

DOI: 10.1158/1078-0432.22446770

Authors: Brigitte C. Widemann, AeRang Kim, Elizabeth Fox, Sylvain Baruchel, Peter C. Adamson, Ashish M. Ingle, Julia Glade Bender, Michael Burke, Brenda Weigel, Diana Stempak, Frank M. Balis, Susan M. Blaney

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362433434

Cites:

Cited by:

Related to: 10